Camptothecin in Cancer Therapy: Current Challenges and Emerging Strategies with Nanoemulsions

Area of Science:

• Pharmacology and Nanomedicine
• Molecular Biology
• Oncology

Background:

• Camptothecin (CPT) is a natural alkaloid with potent antiproliferative activity via Topoisomerase I (Topo I) inhibition.
• Clinical use of CPT is limited by poor solubility and lactone ring instability, reducing efficacy.
• Approved analogs like irinotecan and topotecan face challenges in drug resistance and side effects.

Purpose of the Study:

• To review recent advances in Camptothecin (CPT) and its analogs for cancer therapy.
• To explore nanoparticle-based delivery systems for improving CPT stability, bioavailability, and effectiveness.
• To outline translational challenges in CPT nanomedicine development.

Main Methods:

• Literature review of Camptothecin (CPT) and its analogs.
• Analysis of nanoparticle delivery platforms (nanoemulsions, liposomes, ADCs).
• Discussion of CPT's mechanism of action and clinical limitations.

Main Results:

• Nanomedicine strategies show potential to enhance CPT stability and bioavailability.
• Delivery systems like nanoemulsions, liposomes, and ADCs offer improved CPT effectiveness.
• Despite advances, challenges in scalability, pharmacokinetics, and regulations persist.

Conclusions:

• Nanoparticle-based delivery systems represent a promising strategy to overcome CPT's limitations in cancer treatment.
• Optimizing CPT delivery can potentially enhance therapeutic efficacy and reduce toxicity.
• Addressing translational challenges is crucial for the clinical success of CPT nanomedicines.